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Treatment options for phlegmasia cerulea dolens 
To the Editors: 
The recent report by Comerota et al. (J VASC SURG 
1994;20:244-54) opens new therapeutic possibilities for 
the treatment of illofemoral venous thrombosis. However, 
there are major differences inboth the short- and long-term 
outcomes for iliofemoral vein and inferior vena caval 
thrombosis, when compared with e much more serious 
variant of venous thrombosis, phlegmasia cerulea dolens 
(PCD). PCD carries a published mortality rate of 25% with 
a 12% to 25% risk of major amputation i survivors, i,~ By 
including two such cases, Comerota et al. have obscured an 
important therapeutic advance for the treatment of PCD. 
Their two cases had multiple catheters, arterial and venous, 
with intraarterial infusion of recombinant tissue- 
plasminogen activator; both had a good clinical outcome. 
We have reported four cases of well-documented PCD 
treated with intraarterial thrombolysis with rapid resolu- 
tion of the pain and swelling and minimal long-term 
edemaJ '4 The key features of this approach are low-dose 
intraarterial thrornbolysis via the common femoral artery, 
with an inferior vena cava filter, preferably a temporary one. 
The arterial route delivers the lyric agent o the capillary bed 
proximal to the venous occlusion, which cannot be 
achieved by the transvenous method of delivery. We believe 
that inferior vena cava fikration is necessary because 
pulmonary embolism (PE) is responsible for 30% of the 
deaths reported in PCD. In Comerota's study three patients 
had pretreatment PEs, and no prospective screening for PE 
was made after intervention i  their series. 
Systemic thrombolytic therapy has little benefit with 
major risks from hemorrhage. Surgical venous thrombec- 
tomy only clears the major venous channels, and success is 
limited to early presentation combined with a therapeutic 
arteriovenous fistula. In PCD the primary lesion is the 
thrombosis within the venous capillary bed leading to the 
compartment syndrome and subsequent gangrene. It is 
therefore logical to deliver the lyric agent o the capillary 
bed by the arterial route, and treatment strategies must 
address this lesion. We attribute the success of the 
treatment in Comerota's two patients with PCD to the use 
of intraarterial thrombolysis with tissue plasminogen 
activator alone. 
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Reply 
To the Editors: 
I appreciate the letter by Mr. Bird and also his 
contributions regarding intraarterial thrombolysis for 
phlegmasia cerulea dolens. I take issue, however, with 
several of his comments. 
Two of the patients reported in our recent study had a 
clinical suspicion of acute arterial occlusion; therefore 
arteriograms were obtained. These patients were specifi- 
cally described in the text of the study, and both patients 
underwent intraarterial catheter-directed thrombolysis. 
However, one of these two patients did not have catheter- 
directed lysis into the venous thrombosis, and that patient 
was taken to the operating room and underwent an 
iliofemoral venous thrombectomy with a cross-pubic 
venous bypass. This patient's condition is summarized in 
Fig. 4 of our study. Our anecdotal experience suggests 
that intraarterial thrombolysis i probably more effective 
than systemic thrombolysis for acute, massive venous 
thrombosis; however, it still has the limitation of minimal 
contact of the plasminogen activator with the venous clot. 
Intrathrombus delivery is likely to be much more effective, 
which was the case in each patient, which we reported (one 
patient receiving intraarterial lysis for acute aortoiliac 
thrombosis also received catheter-directed hrombolysis for 
his iliocaval thrombosis). 
The second issue I have with Mr. Bird's comments i  his 
definition of phlegmasia cerulea dolens. All of our patients 
reported had phlegmasia cerulea dolens. This is defined as 
a condition in which massive occlusion of the venous 
outflow tract produces profound venous hypertension, 
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